Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue: 2012-2019

Historic Non-Current Deffered Revenue for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Sep 2019 value amounting to $900,000.

  • Enanta Pharmaceuticals' Non-Current Deffered Revenue rose 51.77% to $900,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $900,000, marking a year-over-year increase of 51.77%. This contributed to the annual value of $900,000 for FY2019, which is 51.77% up from last year.
  • As of FY2019, Enanta Pharmaceuticals' Non-Current Deffered Revenue stood at $900,000, which was up 51.77% from $593,000 recorded in FY2018.
  • Enanta Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $900,000 for FY2019, and its period low was $593,000 during FY2018.
  • Its 3-year average for Non-Current Deffered Revenue is $723,000, with a median of $676,000 in 2017.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Non-Current Deffered Revenue spiked by 310.46% in 2015, and later dropped by 12.28% in 2018.
  • Enanta Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $628,000 in 2015, then climbed by 10.83% to $696,000 in 2016, then declined by 2.87% to $676,000 in 2017, then decreased by 12.28% to $593,000 in 2018, then spiked by 51.77% to $900,000 in 2019.